Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.


Updates from The Motley Fool

Latest updates on Neurocrine Biosciences from Fool.com.


Stock Performance

NBIX vs. S&P 500 | 2 Year Performance
View Interactive NBIX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Neurocrine Biosciences.
Current Price: $51.20
Prev Close: $53.36
Open: $53.37
Bid: $51.27
Ask: $51.35
Day's Range: $50.41 - $53.54
52wk Range: $31.25 - $58.46
Volume: 418,469
Avg Vol 728,518
Market Cap: $4.41B
P/E (ttm): -37.06
EPS (ttm): -$1.44
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Neurocrine Biosciences.
CAPS Rating 3 out of 5
 
318 Outperform
47 Underperform
CAPS All Stars
 
88 Outperform
6 Underperform

How do you think Neurocrine Biosciences will perform against the market?



You pick for Neurocrine Biosciences is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Kevin C. Gorman, CEO

81% Approve

Based on 3 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Neurocrine Biosciences.

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers